Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.6.0 was added. Several study documents and metadata (PDFs, protocols, IPD plans, collaborators) were removed from the study record.SummaryDifference18%

- Check10 days agoChange DetectedThe page shows a revision update from v3.5.4 to v3.5.5, representing an internal software or content-management update. This does not alter the information presented about the study or its navigation.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedVersion label updated from v3.5.3 to v3.5.4, indicating a minor platform update. There are no evident changes to the study details or page content.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page’s footer/version indicator was updated from **Revision: v3.5.2** to **Revision: v3.5.3**, reflecting a background site update rather than a change to the clinical trial information.SummaryDifference0.0%

- Check61 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.0%

- Check68 days agoChange DetectedIQVIA Pty Ltd was added as a collaborator and Iqvia Pty Ltd was removed, correcting the sponsor/collaborator listing.SummaryDifference0.0%

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.